![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DMKN |
Gene summary for DMKN |
![]() |
Gene information | Species | Human | Gene symbol | DMKN | Gene ID | 93099 |
Gene name | dermokine | |
Gene Alias | UNQ729 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0007009 | UniProtAcc | A3EZ84 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
93099 | DMKN | C06 | Human | Oral cavity | OSCC | 5.12e-06 | 1.81e+00 | 0.2699 |
93099 | DMKN | C08 | Human | Oral cavity | OSCC | 4.64e-68 | 1.47e+00 | 0.1919 |
93099 | DMKN | C09 | Human | Oral cavity | OSCC | 1.42e-55 | 1.74e+00 | 0.1431 |
93099 | DMKN | LP15 | Human | Oral cavity | LP | 4.79e-03 | 1.52e+00 | 0.2174 |
93099 | DMKN | LP17 | Human | Oral cavity | LP | 2.85e-02 | 6.84e-01 | 0.2349 |
93099 | DMKN | SYSMH1 | Human | Oral cavity | OSCC | 3.23e-03 | 1.90e-01 | 0.1127 |
93099 | DMKN | SYSMH2 | Human | Oral cavity | OSCC | 5.19e-11 | 6.38e-01 | 0.2326 |
93099 | DMKN | SYSMH3 | Human | Oral cavity | OSCC | 9.78e-66 | 1.76e+00 | 0.2442 |
93099 | DMKN | SYSMH4 | Human | Oral cavity | OSCC | 1.80e-10 | 3.09e-01 | 0.1226 |
93099 | DMKN | SYSMH5 | Human | Oral cavity | OSCC | 3.23e-17 | 4.75e-01 | 0.0647 |
93099 | DMKN | SYSMH6 | Human | Oral cavity | OSCC | 3.04e-20 | 5.98e-01 | 0.1275 |
93099 | DMKN | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 1.50e-02 | 4.02e-01 | -0.2126 |
93099 | DMKN | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 9.09e-03 | 5.63e-01 | -0.2027 |
93099 | DMKN | GSM5252136_BPH556PrGA1_Fcol | Human | Prostate | BPH | 1.36e-03 | 5.21e-01 | -0.23 |
93099 | DMKN | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 4.09e-02 | 5.03e-01 | -0.23 |
93099 | DMKN | 047563_1562-all-cells | Human | Prostate | BPH | 2.11e-19 | -4.27e-01 | 0.0791 |
93099 | DMKN | Dong_P1 | Human | Prostate | Tumor | 7.31e-27 | 1.09e-01 | 0.035 |
93099 | DMKN | Dong_P3 | Human | Prostate | Tumor | 9.99e-13 | 1.96e-01 | 0.0278 |
93099 | DMKN | Dong_P5 | Human | Prostate | Tumor | 2.08e-07 | -1.85e-01 | 0.053 |
93099 | DMKN | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 9.76e-14 | -3.06e-01 | 0.1545 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00070092 | Cervix | CC | plasma membrane organization | 28/2311 | 142/18723 | 7.85e-03 | 4.14e-02 | 28 |
GO:00717095 | Cervix | N_HPV | membrane assembly | 6/534 | 50/18723 | 2.87e-03 | 2.47e-02 | 6 |
GO:00440915 | Cervix | N_HPV | membrane biogenesis | 6/534 | 55/18723 | 4.64e-03 | 3.47e-02 | 6 |
GO:00717096 | Endometrium | AEH | membrane assembly | 12/2100 | 50/18723 | 8.00e-03 | 4.43e-02 | 12 |
GO:00440918 | Esophagus | ESCC | membrane biogenesis | 38/8552 | 55/18723 | 3.78e-04 | 2.19e-03 | 38 |
GO:00717099 | Esophagus | ESCC | membrane assembly | 35/8552 | 50/18723 | 4.33e-04 | 2.44e-03 | 35 |
GO:00440914 | Liver | Cirrhotic | membrane biogenesis | 25/4634 | 55/18723 | 6.51e-04 | 4.96e-03 | 25 |
GO:00717094 | Liver | Cirrhotic | membrane assembly | 23/4634 | 50/18723 | 8.62e-04 | 6.22e-03 | 23 |
GO:004409111 | Liver | HCC | membrane biogenesis | 37/7958 | 55/18723 | 1.79e-04 | 1.41e-03 | 37 |
GO:007170911 | Liver | HCC | membrane assembly | 34/7958 | 50/18723 | 2.38e-04 | 1.79e-03 | 34 |
GO:00440917 | Oral cavity | OSCC | membrane biogenesis | 35/7305 | 55/18723 | 1.88e-04 | 1.27e-03 | 35 |
GO:00717098 | Oral cavity | OSCC | membrane assembly | 32/7305 | 50/18723 | 3.02e-04 | 1.89e-03 | 32 |
GO:004409113 | Oral cavity | LP | membrane biogenesis | 25/4623 | 55/18723 | 6.27e-04 | 5.71e-03 | 25 |
GO:007170913 | Oral cavity | LP | membrane assembly | 23/4623 | 50/18723 | 8.33e-04 | 7.27e-03 | 23 |
GO:00717097 | Prostate | BPH | membrane assembly | 20/3107 | 50/18723 | 6.88e-05 | 6.78e-04 | 20 |
GO:00440916 | Prostate | BPH | membrane biogenesis | 21/3107 | 55/18723 | 1.02e-04 | 9.39e-04 | 21 |
GO:007170912 | Prostate | Tumor | membrane assembly | 19/3246 | 50/18723 | 4.13e-04 | 3.16e-03 | 19 |
GO:004409112 | Prostate | Tumor | membrane biogenesis | 20/3246 | 55/18723 | 5.74e-04 | 4.13e-03 | 20 |
GO:00070093 | Prostate | Tumor | plasma membrane organization | 36/3246 | 142/18723 | 1.00e-02 | 4.20e-02 | 36 |
GO:00440919 | Skin | cSCC | membrane biogenesis | 26/4864 | 55/18723 | 5.38e-04 | 3.99e-03 | 26 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DMKN | SNV | Missense_Mutation | c.1321N>T | p.Ala441Ser | p.A441S | Q6E0U4 | protein_coding | tolerated(0.1) | benign(0.015) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
DMKN | SNV | Missense_Mutation | c.656N>T | p.Ser219Leu | p.S219L | Q6E0U4 | protein_coding | deleterious(0) | possibly_damaging(0.494) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
DMKN | SNV | Missense_Mutation | novel | c.1124N>T | p.Ala375Val | p.A375V | Q6E0U4 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-WT-AB41-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
DMKN | SNV | Missense_Mutation | rs367798085 | c.388N>A | p.Gly130Ser | p.G130S | Q6E0U4 | protein_coding | tolerated(1) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DMKN | SNV | Missense_Mutation | c.1370N>T | p.Ser457Leu | p.S457L | Q6E0U4 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
DMKN | SNV | Missense_Mutation | c.334G>C | p.Glu112Gln | p.E112Q | Q6E0U4 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
DMKN | SNV | Missense_Mutation | c.1045N>A | p.Glu349Lys | p.E349K | Q6E0U4 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
DMKN | SNV | Missense_Mutation | rs756468266 | c.166N>A | p.Gly56Ser | p.G56S | Q6E0U4 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
DMKN | SNV | Missense_Mutation | novel | c.1015N>A | p.Gly339Arg | p.G339R | Q6E0U4 | protein_coding | tolerated(0.64) | benign(0.381) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
DMKN | SNV | Missense_Mutation | c.334G>C | p.Glu112Gln | p.E112Q | Q6E0U4 | protein_coding | deleterious(0) | possibly_damaging(0.893) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |